Longeveron Appoints Lisa Locklear As Chief Financial Officer, Effective July 31, 2023
Portfolio Pulse from Happy Mohamed
Longeveron Inc. (NASDAQ:LGVN) has announced the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer, effective from July 31, 2023. Locklear, who previously served as Senior Vice President and CFO at Avanir Pharmaceuticals, brings extensive global business and finance experience in the biopharmaceutical industry. Her appointment is expected to strengthen Longeveron's financial foundation and advance its cellular therapy assets.
July 20, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The appointment of Lisa Locklear as CFO is a positive development for Longeveron. Her extensive experience in the biopharmaceutical industry and proven leadership skills could strengthen the company's financial foundation and help advance its cellular therapy assets.
Lisa Locklear's appointment as CFO is likely to have a positive impact on Longeveron's stock. Her extensive experience in the biopharmaceutical industry and proven leadership skills could strengthen the company's financial foundation and help advance its cellular therapy assets. This could potentially lead to increased investor confidence and a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100